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n	 INTRODUCTION
Giant cell arteritis (GCA) is an inflam-matory vasculopathy that preferen-
tially affects medium- and large-sized ar-
teries (1). An association with polymyalgia 
rheumatica occurs and both are probably 
polygenic diseases in which multiple en-
vironmental and genetic factors influence 
susceptibility and severity (1). Pathogenet-
ic studies of GCA may suggest that GCA is 
an antigen driven disease (2). A viral cause 
has been suspected but not confirmed in 
polymyalgia rheumatica and giant-cell ar-
teritis. The epidemiologic evidence that 
there is a similar cyclic fluctuation (every 
six to seven years) in the incidence of gi-
ant-cell arteritis and parvovirus B19 infec-
tion suggests in fact that viruses could have 
a role (3-5). 
Chronic active Epstein-Barr virus infection 
(CAEBV) is characterized by infectious 
mononucleosis-like clinical features and 
elevated titres of EBV antibodies (6). Re-
cently, EBV association with various etio-
logically unknown diseases has been dem-
onstrated through the documentation of the 
presence or increase of viral genomes in 
disease-related lesions (7). 
To the knowledge of authors no association 
has been described between CAEBV and 
GCA. In the present report we describe the 
case of a patient in whom GCA occurred 
during the course of CAEBV suggesting 
that EBV infection may play a pathoge-
netic role in the development of arteritis.
n	 CASE REPORT
The patient was a 81-year-old female who 
suffered from two months of fever, gener-
alized malaise, cervical lymph node en-
largement, and hepatosplenomegaly. Six 
weeks later she complained the onset of 
headache, located over the temporal area 
and consistent with GCA-type headache, 
and was admitted to Palermo University 
Hospital. The patient suffered also from 
pain during swallowing and jaw claudica-
tion. Paresthesia of the scalp, carotidynia, 
or visual disturbances were not present. 
Physical examination on admission re-
vealed enlarged cervical lymph nodes and 
hepatosplenomegaly. The frontal and pari-
etal branches of the superficial temporal ar-
teries were thickened, nodular, tender, and 
erythematous. Laboratory data revealed 
increased ESR and CRP (80 mm/hr and 
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(hemoglobin, 85 g/L), thrombocytope-
nia (platelets, 90 x 109/L), and polyclonal 
gammopathy (IgG, 34.6 g/L; IgA, 5.5 g/L; 
and IgM, 1.6 g/L). Elevated levels of AST 
(2.3, ukat/L), ALT (1.7, ukat/L), and LDH 
(6.2, ukat/L) were seen. Serological tests 
for herpes simplex virus, parvovirus B19, 
and cytomegalovirus were negative. EBV 
antibodies revealed extremely high IgG 
antibody titres against viral capsid antigen 
(VCA) IgG (≥5.120), and against early 
antigen DR (EADR) IgG (≥640). Nega-
tive results for Epstein-Barr nuclear anti-
gens (EBNA) was also observed. Periph-
eral blood was obtained from the patient 
on referral, and viral load was determined 
on peripheral blood mononuclear cells 
(PBMC) by real-time quantitative poly-
merase chain reaction (PCR) with primer 
sets yielding DNA fragments correspond-
ing to the internal repeat 1 and EBNA-2 
regions of the virus genome. PBMC were 
positive for EBV DNA with an EBV loads 
greater than 102.5 copies/mg DNA. The 
amount of EBV DNA was calculated as 
the number of virus copies per microgram 
PBMC. The EBV detection limit in this 
assay was approximately 10 copies/mg 
DNA for PBMC. The diagnosis of GCA 
was considered and 4 temporal arterial 
biopsy specimens were obtained. Histo-
logical examination, on Hematoxylin and 
Eosin stained paraffin embedded sections, 
showed a moderate inflammatory infiltrate 
mainly composed of lymphocytes and his-
tiocytes. Multinucleated giant cells were 
also present into the arterial wall (Fig. 
1). Diagnosis of GCA was made accord-
ing to the ACR criteria (8). Detection of 
EBV DNA through PCR analysis was also 
performed on fresh-frozen specimen of 
the diseased temporal artery tissue. EBV 
genome was clearly detected in temporal 
artery biopsy sample with an EBV loads 
greater than 102.5 copies/mg DNA. 
n	 DISCUSSION
Giant cell arteritis (GCA) is a chronic in-
flammatory disorder with a strong pre-
dilection for elderly people. Although a 
Figure 1 - representative photomicrograph showing 5-µm-thick paraffin embedded sections 
of arterial biopsy specimens obtained from the patient stained with hematoxylin and eosin. 
Infiltration of t lymphocytes around and into the vasa vasorum together with the occurence of 
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correlation between the occurrence of 
infection and the onset of GCA has been 
demonstrated (9), suggesting that infec-
tion may act as a trigger mechanism in 
the pathogenesis of this syndrome, never 
a viral cause has been confirmed and the 
pathogenesis of this arteritis remains still 
unclear. In particular, the study from Can-
kovic and Zarbo (10) failed to confirm an 
association between HSV1, cytomegalovi-
rus, and Epstein-Barr virus in 35 patients 
with histologically positive temporal arter-
ies, apparently ruling out a viral pathogen-
esis of GCA. 
Primary EBV infection usually occurs as-
ymptomatically in early adulthood, but 
sometimes it results in infectious mononu-
cleosis, which resolves spontaneously after 
the emergence of EBV-specific immunity 
(7). EBV may cause chronic infections in 
immunocompetent hosts. In healthy carri-
ers, EBV exists latently in resting memory 
B cells (7), whereas clonal expansion of 
EBV-infected T or NK cells is associated 
with chronic active EBV (CAEBV) infec-
tion (7), probably through the release of 
inflammatory cytokines such as interferon 
gamma, IL-6, or tumor necrosis factor al-
pha. This is the first report, to our knowl-
edge, of the occurrence of GCA in a patient 
affected by CAEBV.
CAEBV infection is characterized by 
chronic or recurrent infectious mononu-
cleosis-like symptoms and by an unusual 
pattern of anti-EBV antibodies (7). Hema-
tologic examination often shows a tendency 
for pancytopenia and polyclonal gammopa-
thy. CAEBV is a disease with a high mor-
tality and high morbidity potentially with 
life-threatening complications, such as in-
terstitial pneumonia, lymphoma, coronary 
artery aneurysms, and central nervous sys-
tem involvement. One of the most common 
characteristics of CAEBV is elevated titres 
of EBV antibody (VCA IgG rl:1280, EADR 
positive or EBNA negative) (llJ2). Proposed 
guidelines for diagnosing CAEBV are: 
1. severe illness lasting more than 6 
months that began as a primary EBV 
infection and that was associated with 
abnormal EBV antibody titres, antiviral 
capsid antigens (VCA) immunoglobu-
lin G (IgG) at least 5120, anti-early an-
tigens (EA) IgG at least 640, or anti-EB 
nuclear antigens (EBNA) less than 2; 
2. histologic evidence of organ involve-
ment such as interstitial pneumonia, 
hypoplasia of some bone marrow ele-
ments, vasculitis, lymphadenitis, per-
sistent hepatitis or splenomegaly; and 
3. increased quantities of EBV in affected 
tissues (7). 
It can not be excluded that giant cell arte-
ritis and EBV infection in our patient may 
have occurred together by chance alone, 
and it should be noted that the detection 
of EBV DNA in the temporal artery speci-
mens does not per se necessarily imply that 
EBV triggered giant cell arteritis. Cases 
of an association between CAEBV and 
large-vessel arteritis, namely coronary ar-
teritis have been however reported (11) and 
the case of CAEBV described herein was 
complicated by the concomitant presence 
of clinical and hystopathologic findings of 
GCA. The characteristic histopathologic 
features were the infiltration of lympho-
cytes and histiocytes into the inflamed ar-
terial wall, together with the occurrence of 
giant cells. Using PCR analysis we clearly 
demonstrated the EBV DNA in the blood 
and inflamed artery of the patients, sug-
gesting that EBV-infection might have par-
ticipated in the pathogenesis of the arteritis 
in this case. 
A model for the pathogenesis of giant-cell 
arteritis has been proposed by Weyand 
and Goronzy (2). In the adventitia antigen 
driven T cells may enter the artery through 
the vasa vasorum, undergo clonal expan-
sion, and produce interferon gamma. Vasa 
vasorum vasculitis could be a primary mo-
ment in the pathogenesis of GCA as dem-
onstrated by their production of cytokines 
of the early innate immune response, such 
as IL-32 (12), a recently described pro-
inflammatory cytokine induced by several 
viruses (13, 14).
We hypothesize that an unusual EBV in-
fection into T lymphocytes occurred in 
our patient and played a role in the patho-
genesis of CAEBV-associated arteritis. 
Although the precise pathogenetic mecha-












BV remain unclear, the vascular changes in 
this case may be suggestive of a CAEBV-
associated disorder. 
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